TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8288

塔斯马尼亚州:: 75 0850 ::塔斯马尼亚州恢复法案 - ACTNOW 临床试验 8288

基本信息

  • 批准号:
    7933249
  • 负责人:
  • 金额:
    $ 50万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-01-01 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

This project, managed the Cancer Therapeutics Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, (DCTD), National Cancer Institute (NCI), was funded with ARRA stimulus funding under the Accelerating Clinical Trials of Novel Oncologic PathWays (ACTNOW) program. The research study supported by this funding is: "A Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma." Trials funded under this ACTNOW will test novel agents (alone, in combination, and with other standard therapies) that target new pathways by which cancer cells grow, metastasize and develop resistance to current treatments. The trials will receive enhanced resources to enable rapid development and approval of the treatment protocol such that 90 days from notification of the award, the trial will either be open to enrollment or in review at the local institutional review board. This timeline is significantly faster than is typically attained by industry-sponsored early clinical trials, and is about 9 months faster than NCI¿s standard approach to trial development. This accelerated timeline is possible due to the resources provided by ARRA. These resources will allow more staff to be hired and devoted to protocol writing and statistical plans, and will increase personnel available for database and case report form development. This set of trials will also be greatly enhanced by the ARRA funding which will permit the use of innovative diagnostic scans, specimen sample collection and assay development and adequate reimbursement for the research costs associated with data management at local sites. Lack of funds for these research costs has traditionally resulted in significant delays in time to study initiation. Avoidance of protracted negotiations with pharmaceutical partners, diagnostic companies, and philanthropic organizations, that have usually been needed to bridge the funding gap unmet by NCI, will permit the trials to be activated more quickly. The purpose of this contract is to conduct Phase 2 and early clinical trials of NCI-sponsored agents, evaluate biologic effects of these agents on their molecular targets, evaluate other relevant biologic effects and determine clinically relevant outcomes/correlates. Major emphasis is on Phase 2 studies, pilot protocols that explore promising combination therapies, and high priority studies that are pivotal for drug development and require rapid initiation, completion, and data reporting. NCI staff notify the Contractor of high priority studies as they are identified. NCI also considers investigator-initiated trials for credit under this contract based on available resources and priorities. The contractor will: o Rapidly conduct clinical trials necessary to assess the anti-tumor activity and carry out the development plans for NCI-sponsored agents of varying classes, many of which are directed at new cancer targets. While the majority of trials will be Phase II, some studies designed to develop or assess dose, schedule and pharmacodynamic questions shall be conducted under this contract. o Obtain and process blood, normal and tumor tissue from patients and carry out imaging evaluations for research purposes when required by the protocols. o Study relevant biologics effects of new agents. o Study relevant pharmacology. o Determine the antitumor activity of selected combinations of antitumor agents or combinations involving radiotherapy; and, o Determine the safety and efficacy of these agents and explore pharmacokinetic/pharmacodynamic correlations in special patient populations, such as those with impaired end-organ function, geriatric populations, under-represented racial and/or ethnic groups in whom differences would be anticipated.
该项目由美国国家癌症研究所(NCI)癌症治疗与诊断部(DCTD)的癌症治疗评估项目(CTEP)管理,由ARRA刺激基金在新型肿瘤途径加速临床试验(ACTNOW)项目下资助。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES ERLICHMAN其他文献

CHARLES ERLICHMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES ERLICHMAN', 18)}}的其他基金

NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
NCI 实验治疗-临床试验网络,重点为 1 期
  • 批准号:
    8724724
  • 财政年份:
    2014
  • 资助金额:
    $ 50万
  • 项目类别:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
以第二阶段为重点的早期治疗开发
  • 批准号:
    8739507
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
以第二阶段为重点的早期治疗开发
  • 批准号:
    8352528
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
以第二阶段为重点的早期治疗开发
  • 批准号:
    8497528
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
以第二阶段为重点的早期治疗开发
  • 批准号:
    8845045
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
Early Therapeutics Development with Phase II Emphasis
以 II 期为重点的早期治疗开发
  • 批准号:
    7789085
  • 财政年份:
    2006
  • 资助金额:
    $ 50万
  • 项目类别:
Early Therapeutics Development with Phase II Emphasis
以 II 期为重点的早期治疗开发
  • 批准号:
    8328537
  • 财政年份:
    2006
  • 资助金额:
    $ 50万
  • 项目类别:
Early Therapeutics Development with Phase II Emphasis
以 II 期为重点的早期治疗开发
  • 批准号:
    8014381
  • 财政年份:
    2006
  • 资助金额:
    $ 50万
  • 项目类别:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
以第二阶段为重点的早期治疗开发
  • 批准号:
    7543364
  • 财政年份:
    2006
  • 资助金额:
    $ 50万
  • 项目类别:
GEMCITABINE, 17-ALLYLAMINOGELDANAMYCIN (17-AAG) AND CISPLATIN
吉西他滨、17-烯丙基氨基格尔德霉素 (17-AAG) 和顺铂
  • 批准号:
    7206127
  • 财政年份:
    2005
  • 资助金额:
    $ 50万
  • 项目类别:

相似国自然基金

贯叶金丝桃素调控proBDNF/p75NTR- γδ T轴在抑郁促进银屑病进展中的机制研究
  • 批准号:
    JCZRQN202500195
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
P75NTR调控巨噬细胞糖酵解在脓毒症肠损伤中的作用和机制研究
  • 批准号:
    2025JJ50633
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
CmWRKY75转录因子调控枸橼C-05溃疡病抗性的分子机制
  • 批准号:
    2025JJ60177
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
SlMAPK4-SlMYB75分子模块调控番茄倍半萜合成抵御二斑叶螨的分子机
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
布比卡因脂质体通过BDNF-TrkB/proBDNF-p75NTR信号通路减轻大鼠中枢神经系统毒性的机制研究
  • 批准号:
    2025JJ81190
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
HSF1/P75NTR信号通路在驱动循环肿瘤干细胞促使肝细胞癌肿瘤转移的作用及机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
p75NTR介导 CD36 内吞负性调控心脏驻留巨噬细胞 胞葬作用在急性心肌梗死后修复的研究
  • 批准号:
    2024JJ5502
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
GPR75基因通过调控胰岛素稳态导致华南鲤生长停滞的机制探究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    15.0 万元
  • 项目类别:
    省市级项目
GRP75介导内质网应激下的内质网-线粒体互作在力学超负荷诱导肌腱病的发病机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    15.0 万元
  • 项目类别:
    省市级项目
黄芪皂苷 II 调控 OPCs 细胞p75NTR/β-catenin/ld2 轴促髓鞘再生改善多发性硬化 症神经损伤作用机制研究
  • 批准号:
    24ZR1466500
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目

相似海外基金

TAS::75 0850::TAS RAPID SCREENING OF INDIVIDUAL CELLS USING SINGLE CELL MASS SPE
TAS::75 0850::TAS 使用单细胞群 SPE 快速筛选单个细胞
  • 批准号:
    8353018
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - TISSUE SOURCE SITE (TSS) IN SUP
ARRA::是::ARRA TAS::75 0850::TAS 恢复法案 - SUP 中的组织源站点 (TSS)
  • 批准号:
    8166071
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - TISSUE SOURCE SITE (TSS) IN SUP
ARRA::是::ARRA TAS::75 0850::TAS 恢复法案 - SUP 中的组织源站点 (TSS)
  • 批准号:
    8166070
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - SEQUENCING FOR THE CANCER GENOM
ARRA::YES::ARRA TAS::75 0850::TAS 恢复法案 - 癌症基因组测序
  • 批准号:
    8166066
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - TISSUE SOURCE SITE (TSS) IN SUP
ARRA::是::ARRA TAS::75 0850::TAS 恢复法案 - SUP 中的组织源站点 (TSS)
  • 批准号:
    8166068
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - SEQUENCING FOR THE CANCER GENOM
ARRA::YES::ARRA TAS::75 0850::TAS 恢复法案 - 癌症基因组测序
  • 批准号:
    8166074
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - TISSUE SOURCE SITE (TSS) NETWOR
ARRA::YES::ARRA TAS::75 0850::TAS 恢复法案 - 组织源站点 (TSS) 网络
  • 批准号:
    8166054
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - TISSUE SOURCE SITE (TSS) NETWOR
ARRA::YES::ARRA TAS::75 0850::TAS 恢复法案 - 组织源站点 (TSS) 网络
  • 批准号:
    8166058
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
TAS::75 0850::TAS RECOVERY-BIOMARKER BASED VALIDATION OF DIET AND PHYSICAL ACTIV
TAS::75 0850::TAS 恢复-基于生物标志物的饮食和身体活动验证
  • 批准号:
    8177670
  • 财政年份:
    2010
  • 资助金额:
    $ 50万
  • 项目类别:
TAS::75 0850::TAS RECOVERY ACT ACTNOW CLINICAL TRIAL SUPPORT - CTEP IT Support
TAS::75 0850::TAS 恢复法案 ACTNOW 临床试验支持 - CTEP IT 支持
  • 批准号:
    8919813
  • 财政年份:
    2009
  • 资助金额:
    $ 50万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了